$0

ALLO-501A’s ALPHA2 Trial Expands to Europe and Australia; EXPAND Study to Open Enrollment in Europe; ALLO-316’s Initial Results Postponed to Early 2024; Allogene’s Q3 2023 Earnings Call Summary

On Thursday, November 2, Allogene held its Q3 2023 earnings call (press release), highlighting the expansion of the Ph1/2 ALPHA2 trial, evaluating ALLO-501A (allogeneic CD19 CAR-T) in ≥3L LBCL, into Europe and Australia and the opening of recruitment in the Ph2 EXPAND trial, studying the use of ALLO-647 (anti-CD52 mAb) as part of the lymphodepletion regimen, in Europe. Additionally, the company delayed the data readout from ALLO-316’s (allogeneic CD70 CAR-T) Ph1 TRAVERSE trial for r/r ccRCC to early 2024 and noted the upcoming presentation of 2 analyses from the ALPHA2 study at ASH 2023. Below, Celltelligence provides insights on Allogene’s difficulties in the onboarding process for the EXPAND study, while discussing the potential development of the Ph3 ALPHA3 trial in earlier line LBCL and the initial interest of the company in non-oncology indications. 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.